0
  • Notifications
  • No notifications yet

  • View All Notifications
ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Australian Tga Approves Key Label Updates To Camurus Buvidal To Treat Opioid Dependence
News Feed
course image
  • 06 May 2021
  • Admin
  • News Article

Australian TGA Approves Key Label Updates To Camurus’ Buvidal To Treat Opioid Dependence

Camurus announced that the Australian regulatory agency, the Therapeutic Goods Administration (TGA), has approved key label updates to Buvidal Weekly and Buvidal Monthly (buprenorphine) modified-release solutions for injection.The approval includes: a new higher Buvidal Monthly 160 mg dose, direct initiation onto Buvidal Weekly, removing the requirement to be stabilised on sublingual buprenorphine prior to commencing treatment with Buvidal and changing the contraindications in pregnancy and lactation to precautions.In 2020 over 53,000 Australians received treatment for their opioid dependence, which represents a 4.7% increase on the previous year. This was the largest increase in treatment delivery in the past decade and has been attributed to the introduction of long-acting injectable buprenorphine treatment which has increased treatment access and capacity.“This welcome approval by the TGA provides additional opportunities to individualize treatment with Buvidal according to patients medical needs”, says Fredrik Tiberg, PhD, president & CEO. “Aligned with the EU label, Australian patients can now be directly initiated directly onto Buvidal Weekly, allowing a rapid transfer to long-acting therapy and avoiding the need for daily dosing.”Camurus will now initiate the process for reimbursement for the 160 mg dose through the Pharmaceutical Benefits Advisory Committee process.Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form